|
1
|
Chen W, Huang Y, Pan W, Xu M and Chen L:
Strategies for developing PD-1 inhibitors and future directions.
Biochem Pharmacol. 202(115113)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21(28)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ghahremani Dehbokri S, Alizadeh N,
Isazadeh A, Baghbanzadeh A, Abbaspour-Ravasjani S, Hajiasgharzadeh
K and Baradaran B: CTLA-4: As an immunosuppressive immune
checkpoint in breast cancer. Curr Mol Med. 23:521–526.
2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chennamadhavuni A, Abushahin L, Jin N,
Presley CJ and Manne A: Risk factors and biomarkers for
immune-related adverse events: A practical guide to identifying
high-risk patients and rechallenging immune checkpoint inhibitors.
Front Immunol. 13(779691)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Darnell EP, Mooradian MJ, Baruch EN,
Yilmaz M and Reynolds KL: Immune-related adverse events (irAEs):
Diagnosis, management, and clinical pearls. Curr Oncol Rep.
22(39)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Das S and Johnson DB: Immune-related
adverse events and anti-tumor efficacy of immune checkpoint
inhibitors. J Immunother Cancer. 7(306)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cozma A, Sporis ND, Lazar AL, Buruiana A,
Ganea AM, Malinescu TV, Berechet BM, Fodor A, Sitar-Taut AV, Vlad
VC, et al: Cardiac toxicity associated with immune checkpoint
inhibitors: A systematic review. Int J Mol Sci.
23(10948)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dolladille C, Ederhy S, Sassier M, Cautela
J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF,
et al: Immune checkpoint inhibitor rechallenge after immune-related
adverse events in patients with cancer. JAMA Oncol. 6:865–871.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Salvi A, Di Lenarda A, Dreas L, Silvestri
F and Camerini F: Immunosuppressive treatment in myocarditis. Int J
Cardiol. 22:329–338. 1989.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rubio-Infante N, Ramirez-Flores YA,
Castillo EC, Lozano O, Garcia-Rivas G and Torre-Amione G: A
systematic review of the mechanisms involved in immune checkpoint
inhibitors cardiotoxicity and challenges to improve clinical
safety. Front Cell Dev Biol. 10(851032)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cooper LT Jr, Berry GJ and Shabetai R:
Idiopathic giant-cell myocarditis-natural history and treatment.
Multicenter giant cell myocarditis study group investigators. N
Engl J Med. 336:1860–1866. 1997.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Moslehi J, Lichtman AH, Sharpe AH,
Galluzzi L and Kitsis RN: Immune checkpoint inhibitor-associated
myocarditis: Manifestations and mechanisms. J Clin Invest.
131(e145186)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Norwood TG, Westbrook BC, Johnson DB,
Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ and Conry
RM: Smoldering myocarditis following immune checkpoint blockade. J
Immunother Cancer. 5(91)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Giuliano AE, Edge SB and Hortobagyi GN:
Eighth edition of the AJCC cancer staging manual: Breast cancer.
Ann Surg Oncol. 25:1783–1785. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ammirati E and Moslehi JJ: Diagnosis and
treatment of acute myocarditis: A review. JAMA. 329:1098–1113.
2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Matsumori A: Myocarditis and autoimmunity.
Expert Rev Cardiovasc Ther. 21:437–451. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cooper LT Jr: Myocarditis. N Engl J Med.
360:1526–1538. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lampejo T, Durkin SM, Bhatt N and Guttmann
O: Acute myocarditis: Aetiology, diagnosis and management. Clin Med
(Lond). 21:e505–e510. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Olejniczak M, Schwartz M, Webber E,
Shaffer A and Perry TE: Viral myocarditis-incidence, diagnosis and
management. J Cardiothorac Vasc Anesth. 34:1591–1601.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rose NR: Myocarditis: Infection versus
autoimmunity. J Clin Immunol. 29:730–737. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ling RR, Ramanathan K, Tan FL, Tai BC,
Somani J, Fisher D and MacLaren G: Myopericarditis following
COVID-19 vaccination and non-COVID-19 vaccination: A systematic
review and meta-analysis. Lancet Respir Med. 10:679–688.
2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kgokolo MCM, Anderson K, Siwele SC, Steel
HC, Kwofie LLI, Sathekge MM, Meyer PWA, Rapoport BL and Anderson R:
Elevated levels of soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and
systemic inflammatory stress as potential contributors to immune
suppression and generalized tumorigenesis in a cohort of South
African xeroderma pigmentosum patients. Front Oncol.
12(819790)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Im E, Sim DY, Lee HJ, Park JE, Park WY, Ko
S, Kim B, Shim BS and Kim SH: Immune functions as a ligand or a
receptor, cancer prognosis potential, clinical implication of VISTA
in cancer immunotherapy. Semin Cancer Biol. 86:1066–1075.
2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhou X, Khan S, Huang D and Li L: V-Set
and immunoglobulin domain containing (VSIG) proteins as emerging
immune checkpoint targets for cancer immunotherapy. Front Immunol.
13(938470)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dall'Olio FG, Marabelle A, Caramella C,
Garcia C, Aldea M, Chaput N, Robert C and Besse B: Tumour burden
and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol.
19:75–90. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang L, Mai W, Jiang W and Geng Q:
Sintilimab: A promising anti-tumor PD-1 antibody. Front Oncol.
10(594558)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hoy SM: Sintilimab: First global approval.
Drugs. 79:341–346. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Grabie N, Gotsman I, DaCosta R, Pang H,
Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH and Lichtman
AH: Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8 +
T-cell-mediated injury in the heart. Circulation. 116:2062–2071.
2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Inno A, Tarantini L, Parrini I,
Spallarossa P, Maurea N, Bisceglia I, Silvestris N, Russo A and
Gori S: Cardiovascular effects of immune checkpoint inhibitors:
More than just myocarditis. Curr Oncol Rep. 25:743–751.
2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Johnson DB, Balko JM, Compton ML, Chalkias
S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et
al: Fulminant myocarditis with combination immune checkpoint
blockade. N Engl J Med. 375:1749–1755. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Reuben A, Petaccia de Macedo M, McQuade J,
Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H,
et al: Comparative immunologic characterization of autoimmune giant
cell myocarditis with ipilimumab. Oncoimmunology.
6(e1361097)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Grabie N, Lichtman AH and Padera R: T cell
checkpoint regulators in the heart. Cardiovasc Res. 115:869–877.
2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ise W, Kohyama M, Nutsch KM, Lee HM, Suri
A, Unanue ER, Murphy TL and Murphy KM: CTLA-4 suppresses the
pathogenicity of self antigen-specific T cells by cell-intrinsic
and cell-extrinsic mechanisms. Nat Immunol. 11:129–135.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Zhang C, Qin S and Zuo Z: Immune-related
myocarditis in two patients receiving camrelizumab therapy and
document analysis. J Oncol Pharm Pract. 28:1350–1356.
2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Mahmood SS, Fradley MG, Cohen JV, Nohria
A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R,
Chen CL, Gupta D, et al: Myocarditis in patients treated with
immune checkpoint inhibitors. J Am Coll Cardiol. 71:1755–1764.
2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Varricchi G, Galdiero MR, Marone G,
Criscuolo G, Triassi M, Bonaduce D, Marone G and Tocchetti CG:
Cardiotoxicity of immune checkpoint inhibitors. ESMO Open.
2(e000247)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lee SH, Cho I, You SC, Cha MJ, Chang JS,
Kim WD, Go KY, Kim DY, Seo J, Shim CY, et al: Cancer
therapy-related cardiac dysfunction in patients treated with a
combination of an immune checkpoint inhibitor and doxorubicin.
Cancers (Basel). 14(2320)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wieczorkiewicz P, Supel K, Przybylak K,
Kacprzak M and Zielinska M: Acute coronary syndrome versus acute
myocarditis in young adults-value of speckle tracking
echocardiography. PLoS One. 17(e0271483)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Canan A, Van Woerkom RC and Rajiah PS:
Myocarditis mimicking stress-induced (takotsubo) cardiomyopathy.
Tex Heart Inst J. 49(e207430)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Pollack A, Kontorovich AR, Fuster V and
Dec GW: Viral myocarditis-diagnosis, treatment options, and current
controversies. Nat Rev Cardiol. 12:670–680. 2015.PubMed/NCBI View Article : Google Scholar
|
